## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.2% below STRENGTH zone (3.0-6.0%); PEG 2.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($81.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. GE HealthCare to announce fourth quarter and full year 2025 results on February 4, 2026**
- Source: www.sharewise.com | 20260105T153759 | Neutral | Relevance: 100%
- GE HealthCare (NASDAQ: GEHC) announced it will release its fourth quarter and full year 2025 financial results on Wednesday, February 4, 2026, before market open. Management will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the results. The company, a global healthcare solutions provider with approximately 53,000 colleagues, was recognized among Fortune's 2025 World’s Most Admired Companies.

**2. With 86% ownership of the shares, GE HealthCare Technologies Inc. (NASDAQ:GEHC) is heavily dominated by institutional owners**
- Source: Simply Wall Street | 20260103T150744 | Somewhat-Bullish | Relevance: 100%
- Institutional investors own 86% of GE HealthCare Technologies Inc. (NASDAQ:GEHC) shares, giving them significant influence over the company's share price. The largest shareholders include The Vanguard Group (11%), with the top 16 investors collectively holding 51%. Insiders own less than 1% of the company, highlighting the dominance of institutional holdings.

**3. Bank of America Increases GE HealthCare Technologies (NASDAQ:GEHC) Price Target to $92.00**
- Source: MarketBeat | 20260105T134618 | Bullish | Relevance: 100%
- Bank of America has increased its price target for GE HealthCare Technologies (NASDAQ:GEHC) to $92.00 from $82.00, suggesting an 11.08% upside from the stock's previous close. Despite a "neutral" rating from Bank of America, several other firms have also raised targets for GEHC, which recently beat quarterly earnings expectations and provided positive FY2025 guidance. The company’s stock performance shows a 1-year low of $57.65 and a 1-year high of $94.80, with institutional investors owning 82.06% of the stock.

**4. Cwm LLC Raises Stock Position in GE HealthCare Technologies Inc. $GEHC**
- Source: MarketBeat | 20260103T100810 | Bullish | Relevance: 100%
- Cwm LLC significantly increased its stake in GE HealthCare Technologies Inc. by 181.8% in Q3, now holding 34,393 shares valued at $2.583 million. Analyst sentiment for GEHC is a "Moderate Buy" with a consensus target of $87.09, and the company recently reported beating quarterly earnings estimates and declared a quarterly dividend.

**5. With 86% ownership of the shares, GE HealthCare Technologies Inc. (NASDAQ:GEHC) is heavily dominated by institutional owners**
- Source: Simply Wall Street | 20260103T150800 | Bullish | Relevance: 96%
- Institutional investors hold a significant 86% ownership stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC), indicating their substantial influence over the company's share price. The largest shareholder is The Vanguard Group, Inc. with 11%, and the top 16 shareholders collectively control 51% of the ownership. Individual investors, or the general public, hold a 13% stake, while insiders own less than 1% of the very large company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | B of A Securiti | $92 | $82 | +12% |
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | B of A Securiti | main | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.46 elevated, pricing in significant growth expectations. Forward P/E 17.2x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (3 raises, avg +10%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.8B |
| Beta | 1.23 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.46 |
| Forward P/E | 17.2 |
| Current P/E | 18.7 |
| YoY Growth | 8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.9% to 2.2% (+3.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.8pp (needs >3.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.16% (CS: 68) | Neutral |
| RSI_14 | 61.4 | Neutral |
| MACD Histogram | -0.25 | Bearish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.073x | Above |
| vs SMA200 | 1.142x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $85.04
- **Stop Loss:** $81.56 (4.1% risk)
- **Target:** $88.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 247
- **Position Value:** $21,004.88
- **Portfolio %:** 21.00%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*